In this Healio Video Perspective, Roger A. Goldberg, MD, MBA, overviews the results of the phase 2 ARCHER study investigating intravitreal ANX007 for the treatment of geographic atrophy, presented at the Retina Society meeting.
According to Goldberg, the primary endpoint of the study was the change in geographic atrophy lesion area, and prespecified functional endpoints included changes in best corrected visual acuity, low luminance visual acuity and low luminance visual deficit.
“ANX007, the ARCHER phase 2 study, showed consistent demonstration of visual function benefits across a whole